Bionano Announces Software Marketing Agreement With Revvity for Newborn Sequencing Research
Bionano Announces Software Marketing Agreement With Revvity for Newborn Sequencing Research
- Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow
- VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities
- Bionano已與Revvity簽署了一項軟件營銷協議,在該協議下,Revvity將將Bionano的VIA軟件營銷並推廣至其新生兒測序研究工作流的下一代測序(NGS)客戶。
- 預計VIA將通過爲NGS解決方案報告中添加CNV評估和優化工作流的解釋能力,從而增強Revvity的新生兒測序解決方案。
SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE: RVTY) under which Revvity will market and commercialize Bionano's VIA software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity's sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow's interpretation capabilities.
2024年6月20日,美國生命科學公司Bionano Genomics, Inc.(納斯達克股票代碼:BNGO)今日宣佈,已與Revvity, Inc. (紐交所股票代碼:RVTY)簽署了一項軟件營銷協議,Revvity將將Bionano的VIA軟件作爲其新生兒測序研究工作流程的一部分進行推廣。預計VIA將通過爲其NGS工作流程中添加CNV評估和優化工作流的解釋能力,從而增強Revvity全面的測序解決方案。
Revvity's end-to-end workflow includes DNA extraction of dried blood spot samples, sample quality control and quantification, automated library preparation, sequencing, using systems from Element Biosciences or Illumina, a hybridization-based NGS panel designed to identify variants in over 390 genes that are relevant for newborn sequencing research, cloud-based data management, and analysis with VIA software.
Revvity的端到端工作流程包括對幹血斑樣本進行DNA提取、樣本質量控制和定量、自動化文庫製備、使用Element Biosciences或Illumina系統進行測序、基於雜交的NGS面板設計用於鑑定與新生兒測序研究相關的390多個基因中的變異、雲數據管理和通過VIA軟件進行分析。
Erik Holmlin, PhD, president and chief executive officer of Bionano, said, "Bionano is focused on transforming the way the world sees the genome and our VIA software is not only a powerful tool for optical genome mapping visualization, interpretation and reporting, but is also widely used for applications in NGS. We are thrilled to be supporting Revvity in enabling the adoption of next generation sequencing solutions in newborn sequencing research applications around the world."
Bionano總裁兼首席執行官Erik Holmlin, PhD表示:Bionano專注於改變人們看待基因組的方式,我們的VIA軟件不僅是一種強大的光學基因圖譜可視化、解釋和報告工具,而且在NGS應用領域廣泛應用。我們很高興能夠支持Revvity在促進全球新生兒測序研究應用中採納下一代測序解決方案。
About Bionano
關於Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
Bionano是一家可以爲研究人員和臨床醫生揭示生物學和醫學中具有挑戰性問題答案的基因組分析解決方案供應商。該公司的使命是通過光學基因組圖譜(OGM)解決方案、診斷服務和軟件改變世界看待基因組的方式。本公司提供OGM解決方案適用於基礎、應用和臨床研究應用。公司還提供行業領先的、平台無關的基因組分析軟件解決方案和使用專有的等電聚焦(ITP)技術的核酸提取和純化解決方案。通過其名爲Lineagen, Inc. d/b/a Bionano Laboratories的業務,公司還提供基於OGM的診斷測試服務。
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Except as specifically noted otherwise, Bionano's products are for research use only and not for use in diagnostic procedures.
除特別註明外,Bionano的產品僅供科研使用,不得用於診斷程序。
Forward-Looking Statements of Bionano
Bionano的正式聲明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the utility of VIA software for NGS and newborn sequencing research applications; the ability and utility of VIA software for assessing CNVs in NGS workflows for research applications; the ability and utility of VIA software to enhance the report interpretation capabilities of Revvity's workflow for research applications; the ultimate success of Revvity's solutions and continued use of the VIA software; and other statements which are not historical facts. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and potential future bank failures, supply chain disruptions, global pandemics, inflation and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; the failure of VIA software to be useful for NGS and newborn sequencing research applications; the failure of VIA software to assess CNVs in NGS workflows for research applications; the failure of VIA software to enhance the report interpretation capabilities of Revvity's workflow for research applications including newborn sequencing research applications; changes in our strategic and commercial plans or the strategic or commercial plans of our partner; our need and ability to obtain sufficient financing to fund our strategic plans and commercialization efforts, our ability to effectively manage our uses of cash, and our ability to continue as a "going concern"; the ability of institutions to obtain funding to support adoption or continued use of our technologies and the solutions offered by our partner; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
本新聞稿包含根據1995年《私人證券訴訟改革法案》(Private Securities Litigation Reform Act of 1995)的規定所做的前瞻性聲明。像"預計"、"將"等類似用語(以及其他有關未來事件、情況或環境的詞語或用語)表達了未來事件或結果的不確定性,目的是識別這些前瞻性聲明。前瞻性聲明包括關於我們意圖、信仰、預測、前景、分析或關於我們的:VIA軟件在NGS和新生兒測序研究應用領域的作用;VIA軟件對於評估CNV對於研究應用的價值;VIA軟件如何優化解釋Revvity與新生兒測序相關的工作流的能力;Revvity解決方案的最終成功以及持續使用VIA軟件;以及其他並非歷史事實的聲明。這些前瞻性聲明中的每一個都涉及風險和不確定性。實際結果或發展可能與這些前瞻性聲明所預示或暗示的結果不同。導致這種差異的因素包括:地緣政治和宏觀經濟發展的影響,例如最近和可能未來的銀行破產、供應鏈中斷、全球大流行、通脹和烏俄和以巴衝突對我們的業務和全球經濟的影響;一般市場條件;VIA軟件在NGS和新生兒測序研究應用領域中未能發揮作用、在研究應用中未能評估CNVs、未能對新生兒測序研究應用的Revvity工作流的報告解釋能力進行優化的風險;我們和我們合作伙伴的戰略和商業計劃或我們的合作伙伴的戰略或商業計劃的變化;我們獲得足夠資金來資助我們的戰略計劃和商業化工作的需求和能力、我們有效管理我們的現金使用並作爲"持續經營"進行的能力;機構獲得資金來支持我們的技術以及我們的合作伙伴所提供的解決方案的採納或持續使用的風險;以及我們的業務和財務狀況所固有的風險和不確定性,包括在我們向證券交易委員會提交的文件中所描述的風險和不確定性,包括但不限於我們於2023年12月31日結束的年度報告中的風險和不確定性以及之後我們向證券交易委員會提交的其他文件中的風險和不確定性。本新聞稿中包含的所有前瞻性聲明僅在其發表之日起有效,並基於管理層在該日期的假設和估計。我們不會公開更新任何前瞻性聲明,無論是因爲獲得了新信息、未來事件的發生還是其他原因。
CONTACTS
聯繫方式
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
公司聯繫人:
埃裏克·霍爾姆林,首席執行官
bionano genomics,公司。
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
投資者關係:
大衛·霍姆斯
吉爾馬汀集團
+1 (858) 888-7625
IR@bionano.com
Source: Bionano Genomics
來源:bionano genomics